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Abstract
We have recently shown that the immunophilin FKBP5 (also known as FKBP51) is a scaffolding protein that can enhance
PHLPP-AKT interaction and facilitate PHLPP-mediated dephosphorylation of Akt Ser473, negatively regulating Akt activation
in vitro. Therefore, FKBP5 might function as a tumor suppressor, and levels of FKBP5 would affect cell response to
chemotherapy. In the current study, we have taken a step forward by using a pancreatic cancer xenograft mice model to
show that down regulation of FKBP5 in shFKBP5 xenograft mice promotes tumor growth and resistance to gemcitabine,
a phenomenon consistent with our previous findings in pancreatic cell lines. In addition, we also found that inhibitors
targeting the Akt pathway, including PI3K inhibitor, Akt inhibitor and mTOR inhibitor had a different effect on sensitization
to gemcitabine and other chemotherapeutic agents in cell lines, with a specific Akt inhibitor, triciribine, having the greatest
sensitization effect. We then tested the hypothesis that addition of triciribine can sensitize gemcitabine treatment,
especially in shFKBP5 pancreatic cancer xenograft mice. We found that combination treatment with gemcitabine and
triciribine has a better effect on tumor inhibition than either drug alone (p,0.005) and that the inhibition effect is more
significant in shFKBP5 xenograft mice than wt mice (p,0.05). These effects were correlated with level of Akt 473
phosphorylation as well as proliferation rate, as indicated by Ki67 staining in xenograft tumor tissues. These results provide
evidence in support of future clinical trials designed to tailor therapy based on our observations.
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Introduction
Cytidine analogues such as gemcitabine are widely used to treat
a variety of cancers. Gemcitabine remains standard therapy for
pancreatic cancer in the adjuvant and palliative settings [1,2,3].
However, the gemcitabine response rate is very low in pancreatic
cancer, with only an 18% 1 year survival rate [4]. This poor
survival rate is primarily because of the lack of early detection and
frequent metastasis of primary tumors into lymph nodes and
surrounding organs, such as the liver and stomach [5,6,7]. As a step
toward individualized gemcitabine therapy in order to achieve
better outcomes, we previously performed a genome wide
association study using 197 individual lymphoblastoid cell lines
[8,9] and identified a protein, FKBP5, that showed a significant
effect on gemcitabine response in tumor cells by negatively
regulating Akt phosphorylation at serine 473 [10,11]. Phosphor-
ylation of Akt activates the Akt pathway, which plays a critical role
in tumorigenesis and chemoresistance [12,13,14,15]. Therefore,
low FKBP5 expression renders tumor cells resistant to many
chemotherapeutic agents, including gemcitabine [8]. In addition,
FKBP5 expression is low or lost in many pancreatic cancer cell
lines and pancreatic cancer patient samples, correlating with
increased Akt Ser473 phosphorylation [10].
These results suggested that FKBP5 might be a tumor
suppressor and that levels of FKBP5 might determine patients’
response to chemotherapy. If that is correct, patients with low
levels of FKBP5 and Akt hyperactivation might benefit from the
addition of inhibitors targeting the Akt pathway. In the current
study, we tested that hypothesis by using an FKBP5 knockdown
pancreatic cancer xenograft mouse model (shFKBP5) and the
results of these experiments may form a foundation for future
clinical translational studies. We found that shFKBP5 xenograft
mice showed a significant increase in tumor burden compared
with wtFKBP5, and that these tumors were more resistant to
gemcitabine treatment. While both wt and shFKBP5 xenograft
mice were able to benefit from combination therapy with
gemcitabine and the Akt inhibitor, triciribine (TCN), shFKBP5
mice showed a greater effect after combination treatment.
Materials and Methods
Cell Lines
The human pancreatic cancer cell lines SU86, ASPC1, and
BXPC3 were gifts from Dr. Daniel D. Billadeau, Mayo Clinic.
Human breast cancer cell lines HS578T (HTB-126
TM) and MCF7
(HTB-22
TM) were obtained from the American Type Culture
Collection (ATCC). The pancreatic cancer cell lines were cultured
in RPMI 1640 supplemented with 10% fetal bovine serum, and
maintained in an incubator with a humidified atmosphere of 5%
CO2 at 37uC. The human breast cancer cells were cultured with
DMEM supplemented with 10% fetal bovine serum under the
conditions described above.
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The FKBP5 shRNA and siRNA used in the knock down studies
were purchased from QIAGEN Inc. (Valencia, CA). Transfection
was performed twice, 24 hours apart, with 200 nM siRNA using
the Lipofectamine
TM RNAiMAX reagent (Invitrogen, Carlsbad,
CA) according to the manufacturer’s instructions.
Sequences for shRNA against FKBP5 were:
First FKBP5 shRNA.
Sense strand: GGG UAA ACA GAU UGA GCA UdTdT.
Antisense strand: AUG CUC AAU CUG UUU ACC CdGdT.
Second FKBP5 shRNA.
Sense strand: AAU AUC CCU CUC CUU UCC GdTdT.
Antisense strand: CGG AAA GGA GAG GGA UAU UdGdT.
Both FKBP5 shRNA duplexes were cloned into pSuper vectors,
and pooled for transfection. The packaging cell line 293T was
infected with retrovirus pSuper–shRNA [16]. The medium was
changed 24 hours later and collected 48 or 72 hours after
transfection. The medium was then filtered through sterile filters
(0.45–mm filter) and was used to infect SU86 cells. Infected cells
were selected with 2 mg/ml puromycin (Sigma-Aldrich). Sixteen
puromycin -resistant colonies that were verified by RT-PCR were
then pooled and stable transfectants were maintained in RPMI
1640 supplemented with 10% FBS and 2 mg/ml puromycin.
Sequences for siRNA against FKBP5 were:
Sense strand: GGG UAA ACA GAU UGA GCA UdTdT.
Antisense strand: AUG CUC AAU CUG UUU ACC CdGdT.
Sequences for negative control siRNA were:
Sense strand: UUC UCC GAA CGU GUC ACG UdTdT.
Antisense strand: ACG UGA CAC GUU CGG AGA AdTdT
Drugs and Cell Proliferation Assays
Gemcitabine was provided by Eli Lilly (Indianapolis, IN).
Triciribine (TCN), rapamycin and LY 294002 were purchased
from EMD Biosciences (San Diego, CA). Etoposide and paclitaxel
were purchased from Sigma-Aldrich (St. Louis, MO). Cytotoxicity
assays with the tumor cell lines were performed with the CellTiter
96H AQueous Non-Radioactive Cell Proliferation Assay (Promega
Corporation, Madison, WI) as described previously [17]. Cyto-
toxicity was assessed by plotting cell survival versus drug
concentration (on a log scale). The IC50 phenotype (effective
dose that kills 50% of the cells) was calculated using a four
parameter logistic model and was used for statistical comparison
between different treatments.
The growth-inhibitory effects of gemcitabine, etoposide and
paclitaxel as well as the effects of combination treatment with
TCN, rapamycin and LY 294002 in BXPC3, ASPC1, SU86,
MCF7 and HS578T cells were also determined using the MTS
assay. Results reported represent the averages of three indepen-
dent replicates.
Transient Transfection and RNA Interference
Human BXPC3 and ASPC1 pancreatic cancer cell lines as well
as MCF7 and HS578T breast cancer cell lines were used to
perform the siRNA studies. The Hiperfect transfection reagent
(QIAGEN) was used for siRNA reverse transfection. Specifically,
cells were seeded into 96-well plates and were mixed with siRNA-
complex, consisting of 10 nM of specific or negative control
siRNA (QIAGEN) and 0.1 ml of lipofectamine
TM RNAiMAX
reagent (Invitrogen, Carlsbad, CA).
Quantitative Real-time Reverse Transcription PCR
Total RNA was isolated from cultured cells with the Qiagen
RNeasy kit (QIAGEN Inc. Valencia, CA), followed by QRT-PCR
performed with the 1-step, Brilliant SYBR Green QRT-PCR
master mix kit (Stratagene, La Jolla, CA). Specifically, primers
purchased from Qiagen were used to perform QRT-PCR using
the Stratagene Mx3005P
TM Real-Time PCR detection system
(Stratagene). All experiments were performed in triplicate with b-
actin as an internal control. Reverse transcribed Universal Human
reference RNA (Stratagene) was used to generate a standard
curve. Control reactions lacked RNA template.
Western Blot Analyses
SDS-PAGE and Western blot analysis were carried out as
previously described [10]. FKBP5 antibodies were raised against
GST fusion proteins containing amino-terminal residues 1–100 of
FKBP5. Antibodies against Akt (#9272), phospho-Akt (Ser473)
(#9271), phospho-Akt (Thr308), FOXO1 (#9454), phospho-
FOXO1 (Thr 24) (#9464), GSK3b (#9315) and phospho-GSK3b
(#9316) were purchased from Cell Signaling Inc (Boston, MA).
Tumor specimens were processed for Western blotting as de-
scribed previously using a Triton X-100-containing lysis buffer
[10]. Blots were developed with Super Signal Chemiluminescence
reagent (Pierce, Rockford, IL).
Athymic Nude Mouse Tumor Formation Assay
All mice used in this study were maintained in the Mayo Clinic
Animal Breeding Facility. All experimental protocols were
reviewed and approved by the Mayo Clinic Institutional Animal
Care and Use Committee (protocol no. A14008), and all studies
were performed according to the methods approved in the
protocol.
SU86 cells stably expressing FKBP5 shRNA and mock cells
were injected subcutaneously into the left inguinal area of 4-week-
old female athymic recessive nude/nude mice (athymic Ncr-nu/
nu: National Cancer Institute-Frederick) using 19-gauge needles
[18,19]. Each mouse received one injection of 5610
6 cells in
200 ml serum-free DMEM. Animals were monitored for activity
and physical condition every day, and the determinations of body
weight and measurement of tumor mass were performed every
3 days. Tumor growth was monitored for 6 weeks, and tumor
volume was calculated as 1/2a6b
2, where ‘‘a’’ stands for the long
diameter and ‘‘b’’ is the short diameter [18,19]. The tumors were
then surgically removed and processed.
Therapy Evaluation
Mice bearing subcutaneous wtFKBP5 SU86 and shFKBP5
SU86 tumors entered the study when tumors reached ,100 mm
3
(day 0) and were randomized to treatment groups, with 5 mice in
each group. Gemcitabine was administered i.p. every 3 days at
concentrations of 25, 50 or 100 mg/kg. For the gemcitabine/
TCN study, four treatment groups were included: (a) vehicle, (b)
TCN, at a dose of 0.5 mg/kg/d in 1.5% sodium bicarbonate
(Thermo Fisher) w/v in water, pH 8.0, administered in 100 mL
intraperitoneal injections once daily from Monday to Friday for 4
weeks, (c) gemcitabine, at a dose of 50 mg/kg in saline,
administered i.p. every 3 days for 4 weeks, or (d) a combination
of the two treatments. There was no evidence of gross toxicity in
the drug-treated animals as measured by weight loss. The tumor
growth rate was calculated with the size measured at each time
point normalized to the initial tumor volume at day 0 when tumors
of shFBKP5 and wtFKBP5 xenograft mice reached 100 mm
3.
Results of the treatment effect were represented by tumor
inhibition ratio, defined as tumor growth rate of shFKPB5 mice
corrected for that of wt FKBP5 mice. Maximal suppression of
tumor growth was used for statistical comparison between different
treatment groups.
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The tissue sections were deparaffinized in xylene, dipped in
decreasing concentrations of ethyl alcohol, and then rehydrated in
distilled water. Antigen retrieval for Ki67 (Abcam, Cambridge,
MA) was performed by placing slides in preheated EDTA as the
retrieval solution in a steamer at 98uC for 30 minutes. The staining
procedure was carried out in a Dako Autostainer Plus. Specifically,
the tissue sections were treated with Peroxidase Blocking Reagent
(Dako, Carpinteria, CA) for 5 minutes and then were washed with
1x Wash Buffer (Dako, Carpinteria, CA), followed by treatment
with Protein Block Serum-Free (Dako, Carpinteria, CA) for 5
minutes. The tissue sections were then incubated with the Ki67
primary antibody for 60 minutes at room temperature, followed by
incubation with the secondary antibody (Dako, Carpinteria, CA)
for 15 minutes. High-sensitivity diaminobenzidine (DAB+) chro-
mogenic substrate system (Dako, Carpinteria, CA) was used for
colorimetric visualization.
Statistical Analysis
The experimental data are expressed as mean 6 SEM.
Differences between control and treated groups were determined
by the use of paired t test or ANOVA, and p,0.01 was considered
to be statistically significant.
Results
Knockdown of FKBP5 Results in Increased Pancreatic
Tumor Growth and Gemcitabine Resistance
Previous studies have demonstrated that FKBP5 expression is
down-regulated in pancreatic cancer and have suggested that
FKBP5 may be involved in the tumorigenesis of pancreatic cancer.
The SU86 pancreatic cancer cell line was stably transfected with
pooled FKBP5 shRNA. We then determined the effect of FKBP5
on the formation of xenograft tumors. There was a dramatic
increase of tumor size in FKBP5 knockdown mice compared with
control mice, indicating that FKBP5 is a potential tumor
suppressor (Figure 1A). As shown in Figure 1A, the tumor volume
was significantly greater in shFKBP5 mice than in control mice. At
day 18, the mean volume was 2006101 mm
3 in control animals
(n=5 mice/group), and 9376103 mm
3 in shFKBP5 mice (n=5;
p,0.001). This trend was consistent until day 30 when the mice
were sacrificed (shFKBP5 mice: 29996298 mm
3, and wtFKBP5
mice: 11906243 mm
3;n = 5 ;p ,0.001). Since our previous
studies showed that the expression level of FKBP5 was correlated
with the sensitivity of pancreatic cancer cells to chemotherapeutic
drugs [10], we next determined whether knockdown of FKBP5
could affect the chemosensitivity of SU86 xenografts to gemcita-
bine in vivo. We first tested the dose effect of gemcitabine with both
wt and shFKBP5 SU86 xenografts once tumors reached the same
size, 100 mm
3. A dose-dependent inhibition of tumor growth was
observed with gemcitabine for all the SU86 xenografts (Figure 1B
and C). FKBP5 wild type SU86 xenografts showed a statistically
significant response to 100 mg/kg of gemcitabine treatment
compared with shFKBP5 SU86 xenografts treated with the same
dose of gemcitabine (Figure 1D, p,0.05), suggesting that low
expression of FKBP5 can cause resistance to gemcitabine. We also
found that at the lower concentrations of gemcitabine, the
wtFKBP5 also exhibited a trend toward better response than
shFKBP5 xenograft mice, although not statistically significant
(data not shown). All treatments were well tolerated, with no
significant body weight loss (Figure 1E and F).
We have previously shown that activated Akt signaling is
associated with low levels of FKBP5 in pancreatic cancer cells
[10]. Therefore, we examined the activity of the Akt pathway in
tumor samples for each cell line. In shFKBP5 xenografts,
phosphorylated Akt-Ser473, FOXO1and GSK3b were signifi-
cantly increased compared with the control (Figure 2, p,0.01).
Addition of gemcitabine had no effect on levels of phosphorylation
for these proteins. These results were consistent with our previous
findings using pancreatic cell lines [10]. Collectively, this series of
experiments suggests that FKBP5 functions as a tumor suppressor
by negatively regulating the Akt pathway in vivo. In addition, the
level of FKBP5 affects sensitivity to gemcitabine treatment
associated with its effect on Akt phosphorylation in the pancreatic
xenograft model.
Akt Inhibitor Sensitizes Tumor Cells with Low FKBP5 to
Chemotherapeutic Agents in vitro
The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is a cell
survival pathway that is important for normal cell growth and
proliferation [20,21,22,23]. This pathway is also an important
target for cancer treatment, including mammalian target of
rapamycin (mTOR) inhibitors, inhibitors of PI3K and inhibitors
of Akt that have already demonstrated clinical efficacy for different
tumors [24]. Since FKBP5 negatively regulates Akt activity, we
would expect that the addition of inhibitors targeting the Akt
pathway might reverse resistance to gemcitabine. To test this
hypothesis, we performed a series of in vitro experiments using
three pancreatic tumor cell lines (ASPC1, BXPC3 and SU86) and
two breast cancer cell lines (MCF7 and HS578T). We selected
three different Akt pathway inhibitors, including an upstream
inhibitor of PI3K, LY294002, a specific Akt inhibitor, triciribine
(TCN) that inhibits phosphorylation of all three isoforms of Akt,
and an mTOR inhibitor, rapamycin. We then evaluated the
cytotoxicity effect of gemcitabine in combination with LY294002,
TCN, and rapamycin, respectively. Table 1 summarizes IC50
values of each treatment for these five cell lines. Our data
confirmed, once again, that knockdown of FKBP5 desensitized
cells to gemcitabine treatment in all of the cell lines tested (Table 1
and Figure S1). LY294002, TCN and rapamycin had very modest
effects when used alone in either FKBP5 knockdown cells or
control cells, especially at the concentrations (10 mM of TCN,
1.4 mM LY294002, and 1 nM rapamysin) that we used for
combination treatments (Figure S2). TCN sensitized both control
and FKBP5 knockdown cells to gemcitabine (Table 1, and Figure
S1, p,0.005). However, the TCN sensitization effect was greater
in FKBP5 knockdown cells than in wtFKBP5 cells (p,0.001)
(Table 1 and Figure S1). The sensitization effects of LY294002
and rapamycin were much less than that of TCN (Table 1
LY294002, p =0.0023,0.3412; rapamycin, p =0.0171,0.931).
We had previously found that level of FKBP5 also affects
response to other chemotherapeutic agents, including etoposide
and taxanes [10]. Therefore, we tested whether TCN could also
sensitize those agents in the four cell lines studied. In all four cell
lines, FKBP5 knockdown made the cells more resistant to
etoposide treatment alone, which is consistent with previous
findings. We found that TCN could significantly sensitize etopo-
side in BXPC3, ASPC1, HS578T and MCF7 cells when
compared IC50 values for etoposide treatment alone vs. different
combination treatments (Table S1). The sensitization effect was
more prominent in cells with FKBP5 knockdown. LY294002
could also sensitize etoposide in BXPC3 and MCF7 cells with both
control and siFKBP5 transfection, while rapamycin had a much
less significant effect in control or FKBP5 knock down cells (Table
S1). Addition of TCN could also sensitize paclitaxel in all four cell
lines (Table S2). However, there was no significant difference in
the degree of the sensitization effect between control and FKBP5
FKBP5 a Biomarker for Pancreatic Cancer Treatment
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on paclitaxel sensitization.
The effects of LY294002, TCN and rapamycin in combination
with gemcitabine on the Akt signaling pathway were also
evaluated in SU86 cells. FKBP5 was knocked down using
siRNA that targets FKBP5 (Figure 3A). Akt 473 phosphorylation
was increased in FKBP5 knock down cells compared with control
(Figure 3B, column 1 for both left and right panels, p,0.005), as
well as downstream signaling molecules, such as phosphorylated
GSK3b and FOXO1 (Figure 3C and D, column 1 for both left
and right panels), consistent with our previous results [10]. TCN
alone was sufficient to inhibit the Akt pathway as shown by
decreased phosphorylation levels of Akt compared with control
(Figure 3B, column 3 for both left and right panels, p,0.005),
GSK3b and FOXO1 (Figure 3C and D, column 3 for both left
and right panels). LY294002 also had an effect on the PI3K-Akt
signaling pathway (Figure 3C and D, column 5 for both left and
right panels). However, rapamycin alone had less of an inhibitory
Figure 1. Loss of FKBP5 expression in pancreatic cancer cells results in increased tumor growth in mice. Mice bearing subcutaneous
wtFKBP5 SU86 and shFKBP5 SU86 tumors entered the study when tumors reached ,100 mm
3 (day 0). All mice were randomized to control or
treatment groups and were treated with vehicle or gemcitabine at doses of 25, 50, and 100 mg/kg intraperitoneally twice per week. (A) Formation of
subcutaneous (s.c.) tumors in wt and shFKBP5 SU86 injected nude mice. Results are represented by the tumor volume measured at each time point.
**P,0.001 (5 mice/group) as compared between wtFKBP5 and shFKBP5 xenografts treated with saline. (B and C) Gemcitabine response in wt or
shFKBP5 xenograft mice. Results are represented by the tumor volume measured at each time point corrected to day 0 when mice entered the study.
(D) shFKBP5 xenografts are resistant to gemcitabine in vivo. Results are represented by tumor inhibition ratio, defined as the measurements of tumor
volume at each time point normalized to day 0 for shFKPB5 mice, corrected for that of wt FKBP5 mice. **P,0.001; *P,0.05 (5 mice/group) as
a comparison of tumor growth inhibition ratio between wtFKBP5 and shFKBP5 treated with 100 mg/kg of gemcitabine. (E and F) Measurements of
body weight for wt and shFKBP5 xenografts. Body weight was recorded for each mouse every 3 days throughout the experiment. Statistical
significance was assessed by two-way ANOVA.
doi:10.1371/journal.pone.0036252.g001
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LY294002 (Figure 3B, C and D, column 7 both left and right
panels). TCN in combination with gemcitabine (Figure 3B, C
and D, column 4 for both left and right panels,) further
decreased the phosphorylation levels of Akt 473, GSK3b and
FOXO1 when compared with either gemcitabine (Figure 3B, C
and D, column 2 for both left and right panels) or TCN
(Figure 3B, C and D, column 3 for both left and right panels)
alone (p,0.005) and this effect was much more significant for
TCN plus gemcitabine than for LY294002 or rapamycin plus
gemcitabine (Figure 3B, C and D, column 6 and 8 for both left
and right panels). Since knockdown of FKBP5 significantly
increased Akt 473 phosphorylation levels, the reduction seen with
TCN plus gemcitabine was much more significant in FKBP5
knockdown cells (Figure 3B, C and D, column 4 for both left and
right panels), confirming our hypothesis that cells with low
FKBP5 might depend more on Akt activation and, therefore,
benefit more from the addition of Akt inhibitor.
Enhanced Tumor Growth Inhibition with TCN Plus
Gemcitabine in vivo
Next, we used our xenograft mice with either wt or shFKBP5
SU86 cells to test whether FKBP5 knockdown mice might benefit
more from the addition of the Akt inhibitor, TCN. Wild type and
FKBP5 knockdown SU86 xenograft tumors were grown in nude
mice. Once xenograft tumors formed, TCN and gemcitabine were
injected i.p. A more rapid tumor growth rate was, once again,
observed in shFKBP5 xenograft mice (Figure 4A and B). To
evaluate antitumor efficacy, tumor-bearing mice were treated with
TCN (0.5 mg/kg/day) i.p. for 4 weeks or gemcitabine (50 mg/kg)
i.p. three times a week for 4 weeks in the presence or absence of
TCN at 0.5 mg/kg, i.p. once a day for 5 days. Monotherapy with
TCN alone was not effective in wt or FKBP5 knockdown
xenografts, and there was no significant difference of maximal
suppression of tumor growth in wt and shFKBP5 xenografts when
treated with 50 mg/kg of gemcitabine alone (Figure 4C). How-
ever, cotreatment with TCN significantly enhanced gemcitabine
antitumor effect compared with either gemcitabine or TCN alone
in both wt and shFKBP5 xenograft mice (p,0.005 for both wt and
shFKBP5) (Figure 4D and E). Greater inhibition effect of TCN
plus gemcitabine was observed in shFBKP5 xenograft mice
compared with wtFKBP5 (p,0.005) (Figure 4F). All treatments
were well tolerated, and no animals died during the course of
treatment. Therefore, the combination of gemcitabine and TCN
showed a good safety profile in mice with no mortality or body
weight loss (Figure 4G and H). Thus, the combination of TCN and
gemcitabine exerted significantly greater in vivo antitumor effects
than either agent alone, especially when the level of FKBP5 was
decreased.
We next examined relative Akt 473 phosphorylation within the
xenograft tumors after different treatments. We found that
gemcitabine-resistant shFKBP5 xenografts had elevated levels of
phosphorylated Akt 473 compared with wtFKBP5 (Figure 5A,
column 1 for both left and right panels, p,0.005) as expected.
TCN alone moderately inhibited phospho-Akt (53.1 6 6.2% of
control) (Figure 5A). Gemcitabine alone only slightly inhibited
phospho-Akt in tumor (Figure 5A). With the addition of TCN,
levels of phosphorylated Akt 473 were significantly reduced
compared with controls (Figure 5A, p,0.005). To further address
the underlying mechanism for inhibition of tumor progression,
proliferation was determined by immunostaining in the xenograft
Figure 2. FKBP5 Regulates Akt Phosphorylation at Ser473 in
vivo. Tumor samples from wtFKBP5 SU86 or shFKBP5 SU86 xenografts
were prepared and analyzed for phosphorylation of Akt and
downstream signaling molecules by Western blot analysis.
doi:10.1371/journal.pone.0036252.g002
Table 1. Combinatory effects of gemcitabine and inhibitors
targeting PI3K-Akt-mTOR pathway in human pancreatic and
breast cancer cells.
Cells Agent IC50 (nM)
a p value
b
Neg.
siRNA siFKBP5
Neg.
siRNA siFKBP5
BXPC3 Gem 7.45 17.53
Gem+TCN 1.179 2.634 0.0005 0.0003
Gem+LY294002 2.842 6.839 0.0023 0.001
Gem+Rap 9.956 12.19 0.1509 0.1755
ASPC1 Gem 4.935 15.48
Gem+TCN 1.725 4.977 0.001 0.0007
Gem+LY294002 3.122 8.343 0.1985 0.0216
Gem+Rap 3.356 13.74 0.0171 0.2744
MCF7 Gem 5.697 15.63
Gem+TCN 1.999 2.925 0.0036 0.0003
Gem+LY294002 4.339 8.509 0.0045 0.0054
Gem+Rap 5.369 10.84 0.9096 0.0769
HS578T Gem 3.447 14.58
Gem+TCN 1.115 2.92 0.003 0.001
Gem+LY294002 4.095 8.177 0.3412 0.0099
Gem+Rap 3.332 9.903 0.931 0.0342
aThe values represent the average of three independent experiments.
bIC50 values between combination treatment vs. Gem along were analyzed
statistically by performing t tests.
Abbreviations: Gem, gemcitabine; TCN, tricirbine; Rap, rapamycin.
doi:10.1371/journal.pone.0036252.t001
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more proliferating tumor cells in shFKBP5 xenografts when
compared with controls (Figure 5B and C). The proliferative
activity was lower in specimens treated with gemcitabine plus
TCN than with gemcitabine alone in both wt and shFKBP5
xenografts (Figure 5D, p,0.01). These results strongly suggest that
the combination of TCN and gemcitabine enhanced inhibition of
the Akt pathway.
Discussion
We recently reported that FKBP5 is a scaffolding protein that
can enhance PHLPP-Akt interaction [10]. The functional
consequence of this interaction results in negative regulation of
Akt activity. Down regulation of FKBP5 results in decreased
PHLPP-Akt interaction and increased Akt phosphorylation at the
Ser473 site [10], suggesting that FKBP5 may function as a tumor
suppressor, an important fact contributing to chemoresistance.
Based on our previous findings with FKBP5 and its role in
chemoresistance [9,10], we tested this hypothesis in vivo using
a xenograft mice model.
We found that tumors in shFKBP5 mice were more resistant to
gemcitabinetreatmentandalsoexhibitedafastertumorgrowthrate
(Figure1A–D).Thisphenomenonappearedtoinvolvetheregulation
of Akt activation, as determined by phosphorylated Akt and
downstream signaling molecules (Figure 2). Since Akt is activated
whenFKBP5isknockeddown,wehypothesizedthattheadditionof
inhibitors targeting this pathway might reverse the drug resistance
phenotype. The PI3K-Akt pathway has multiple drugable targets
[25,26,27,28,29,30,31], so we tested a series of inhibitors targeting
PI3K, Akt and mTOR. We observed different treatment effect in
differentcelllines(Tables1,S1andS2),whichmightbeduetothecell
or tissue specificity. We found that the specific Akt inhibitor, TCN,
whenadministeredtogetherwithgemcitabinehadthebesttreatment
outcome when compared with the other inhibitors tested (Table 1,
and Figure S1), suggesting that the effect of FKBP5 on gemcitabine
response depends mainly on Akt 473 phosphorylation. Consistent
with the treatment outcomes, when we tested molecules within the
AktpathwaythatreflectAktactivation,treatmentwithLY294002or
rapamycin together with gemcitabine showed a less significant
decreaseofAktactivitywhencomparedwithgemcitabineplusTCN
(Figure 3). As shown in Figure 4, even with wt xenografts, the
Figure 3. Effects of gemcitabine, TCN, LY294002, rapamycin and the combination of these agents on Akt signaling pathways in
FKBP5 knock down pancreatic cancer cells. (A) FKBP5 knock down efficiency was determined by RT-PCR and Western blot. (B) SU86 cells were
treated with DMSO (vehicle), 10 nM of gemcitabine alone, or 10 mM of TCN, 1.4 mM LY294002, and 1 nM rapamycin alone or in combination. Dose-
dependent effects of different treatments on cellular viability were tested by MTS assay at 48 hours. Only combined treatment with TCN and
gemcitabine inhibited Akt in vitro. ***P,0.005. (C and D) The combination of TCN and gemcitabine showed the most inhibition of pGSK3b and
pFOXO1 when compared with other treatments. Statistical significance was assessed by t test and a p,0.005 was considered significant as shown by
the asterisks (***).
doi:10.1371/journal.pone.0036252.g003
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effect,suggestingthateveninwtxenografts,Aktishyperactivatedand
inhibitionofthispathwaycouldresultinbettertreatmentoutcomes.
HoweverTCNshowedapoorinhibitioneffectonproliferationwhen
used as a single-agent in spite of the fact that it could reduce Akt
phosphorylation, suggesting that other pathways also contribute to
tumor development.
In addition to the role of FKBP5 in chemoresistance [10], based
on our xenograft models it could also function as a tumor
suppressor through negative regulation of the Akt pathway. As
shown in Figures 3 and 5A, activity of the Akt pathway is
significantly higher in FKBP5 knockdown SU86 xenografts than
that in wild type SU86 xenografts and these observations
correlated with higher tumor growth rates in shFKBP5 mice
Figure 4. TCN sensitizes shFKBP5 pancreatic tumors to gemcitabine. Combination of TCN with gemcitabine effectively inhibited tumor
growth in vivo. Mice with subcutaneously established tumors from wtFKBP5 SU86 or shFKBP5 SU86 cells entered the study when tumors reached
,100 mm
3 (day 0), and were treated with TCN at 0.5 mg/kg daily and/or gemcitabine at 50 mg/kg every 3 days for 30 days. (A) wtFKBP5 mice and
(B) shFKBP5 mice tumor growth rate. ***P,0.005. (C) Comparison of maximal tumor suppression between wt and shFKBP5 xenografts. No significant
difference in maximal suppression of tumor growth was observed for wt and shFKBP5 xenografts when treated with 50 mg/kg of gemcitabine alone.
(D and E) Cotreatment with TCN significantly enhanced gemcitabine antitumor effect in both wt and shFKBP5 xenograft mice. **P,0.001; *P,0.05 (5
mice/group) as a comparison of tumor growth inhibition ratio between TCN plus gemcitabine and gemcitabine alone in wtFKBP5 and shFKBP5
groups, respectively. (F) Loss of FKBP5 expression results in increased sensitization effect for TCN on gemcitabine response. ***P,0.005 as
a comparison of tumor growth inhibition ratio between wtFKBP5 and shFKBP5 mice. Mean 6SEM for five tumors at each data point. (G and H)
Measurements of weight loss in wt and shFKBP5 xenografts. The toxic effects of administration of gemcitabine and gemcitabine plus TCN were
determined by recording body weight for each mouse every 3 days throughout the experiment. ANOVA analysis was performed and p,0.005 was
considered significant as shown by the asterisks (***).
doi:10.1371/journal.pone.0036252.g004
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PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e36252(Figure 1A). Therefore, probably because of the higher basal levels
of Akt activity, shFKBP5 xenografts responded better to combi-
nation treatment, which was seen as enhanced inhibition of tumor
growth (Figure 4F). This phenomenon was also reflected by
decreased Akt 473 phosphorylation levels after gemcitabine and
TCN treatment. The shFKBP5 xenografts showed a more
dramatic decrease in Akt 473 phosphorylation levels wt xenografts
(Figure 5A).
Our in vivo results further confirmed findings observed using the
cell lines [11]. Those studies demonstrated that lack of expression
of FKBP5 led to increased Akt phosphorylation at the regulatory
S473 amino acid residue as well as for downstream genes in the
Akt pathway such as phosphorylated FOXO1 and GSK3b.
Therefore, FKBP5 could be a tumor suppressor in pancreatic
cancer and it could also be a biomarker for response to
chemotherapy, especially gemcitabine therapy, a first line treat-
ment for pancreatic cancer. Our findings that a specific Akt
inhibitor can reverse resistance to gemcitabine in FKBP5
knockdown cells and xenografts indicate that FKBP5 levels might
be used to stratify patients into different treatment arms, such as
gemcitabine or gemcitabine plus an Akt inhibitor. Future clinical
studies will be needed to test this hypothesis. In addition, the
mechanisms underlying differences between the effects of PI3K
inhibition, mTOR inhibition and Akt inhibition in combination
with gemcitabine need to be explored further. PI3K activation
causes phosphatidylinositol-3,4,5-triphosphate (PIP3)-dependent
membrane localization of Akt and PDK1, in which the latter
can phosphorylate Akt 308 [32,33,34]. Therefore, the inhibition of
PI3K might have less effect on 473 phosphorylation. Rapamycin
can potentially activate Akt 473 phosphorylation in an mTOR-2
dependent manner due to relief of feedback inhibition of IGF-1R
signaling [35]. That may explain why treatment with rapamycin
plus gemcitabine failed to show a significant reduction of Akt 473
phosphorylation.
Obviously, these findings have to be confirmed by additional
studies using human samples or transgenic mice. However,
currently it is challenging to obtain adequate clinical samples
with similar clinical characteristics treated with gemcitabine alone
to determine the relationship between FKBP5 and treatment
response since most patients are treated with multiple agents.
Certainly future clinical trials designed to test the effect of this
biomarker will be essential to determine whether FKBP5 can be
used as a biomarker for the selection of treatment for individual
patients.
In summary, the findings presented here indicated the
importance of FKBP5 in pancreatic tumor growth and chemore-
sistance. Moreover, the data suggest that specific Akt inhibitors
might be promising adjuvant therapies for pancreatic cancer,
especially in patients with lower level of FKBP5. These findings
could help individualize therapy to achieve better treatment
outcomes for pancreatic cancer patients.
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Figure S1 TCN sensitizes FKBP52/2 human pancreat-
ic and breast cancer cells to gemcitabine in vitro. (A)
Knockdown efficiency for FKBP5 in BXPC3, ASPC1, MCF7 or
HS578T cells determined by real-time QRT-PCR. (B)-(F).
Cytotoxicity was determined with MTS assays in BXPC3, ASPC1,
SU86, MCF7, and HS578T cells. Cells were treated with vehicle
(DMSO), various concentrations of gemcitabine (0.01, 0.1, 1, 5,
10, 25, 50, 100, and 500 nM) alone or in combination with 10 mM
of TCN, 1.4 mM LY294002, or 1 nM rapamysin. Each data point
is mean for 3 independent experiments. Error bars indicate
standard error of the mean (SEM).
(PDF)
Figure S2 Cytotoxicity of TCN, LY294002 and rapamy-
cin in human pancreatic and breast cancer cells. (A)
Knockdown efficiency for FKBP5 in BXPC3, ASPC1, MCF7 or
HS578T cells determined by real-time QRT-PCR. (B)-(D)
BXPC3, ASPC1, MCF7 or HS578T cells were plated in 96-well
plates, treated for 48 hours with various concentrations of TCN
(0.1, 0.5, 1, 2.5, 5, 10, 25, 50, and 100 mM), LY294002 (0.1, 0.5, 1,
2.5, 5, 10, 25, 50, and 100 mM) and rapamycin (0.1, 0.5, 1, 2.5, 5,
10, 25, 50, and 100 nM), followed by MTS assay as described
under Methods. Each data point is an average of triplicates from 3
independent experiments. Error bars indicate standard error of the
mean (SEM).
(PDF)
Table S1 Combinatory effects of etoposide and inhibi-
tors targeting PI3K-Akt-mTOR pathway in human
pancreatic and breast cancer cells.
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Table S2 Combinatory effects of paclitaxel and inhibi-
tors targeting PI3K-Akt-mTOR pathway in human
pancreatic and breast cancer cells.
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